Al Jazeera on MSN
HIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all.
Nearly 100 community-based organizations have lost their federal HIV-prevention grants this week as the Trump administration redirects dollars to state and local health departments. The funding ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
As individuals with HIV live longer, clinicians face growing challenges involving comorbidities, care coordination, shared ...
For people living with HIV, the road to a promising cancer treatment can be longer than it should be, literally.
The Office of AIDS Research (OAR) at the National Institutes of Health (NIH), in partnership with HeroX, the leading platform ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...
Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...
Most important, however, is pre-exposure prophylaxis, or PrEP. For people at risk, PrEP can prevent HIV infection with extraordinary effectiveness, making it the single most powerful tool we have to ...
September, Fiji's government declared a national emergency because of a startling rise in HIV infections. The country's ...
Dr. Theopista Masenge was at the hospital in Mbeya, Tanzania, rolling out new treatments for children with high HIV viral ...
In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results